NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer

manilatimes.net · 2026-09-29

CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ('NeurAxis” or the 'Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company’s commercial functions, including sales and marketing.

TickrTrends take: NeurAxis, the commercial-stage subsidiary of Boston Scientific (BSX), has appointed Craig Blanchard as Chief Commercial Officer to lead its commercial expansion efforts. This leadership appointment signals the company's preparation to scale its business operations, which represents a potential driver of future revenue growth for BSX's Healthcare segment. Given TickrTrends' current assessment that BSX is undervalued, investors focused on valuation metrics may want to monitor how NeurAxis's commercialization progress translates into measurable revenue contributions and margin expansion in upcoming periods.

Read the full story at manilatimes.net →